Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 11/20 | 0.67 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.67 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 2/20 | 0.42 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.41 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1412941 | 0.89 | P2RX7 (0.54) | P2RX7ABCB11TRPV1 | |
| SCHEMBL1412892 | 0.83 | P2RX7 (0.49) | P2RX7ABCB11HIF1AKDM4EMEN1 | |
| SCHEMBL7085991 | 0.82 | P2RX7 (0.50) | P2RX7ABCB11MEN1MAPTKMT2A | |
| SCHEMBL1413016 | 0.82 | P2RX7 (0.75) | P2RX7ABCB11HIF1A | |
| SCHEMBL1412983 | 0.81 | P2RX7 (0.48) | P2RX7ABCB11TP53 | |
| SCHEMBL1412901 | 0.80 | P2RX7 (1.00) | P2RX7ABCB11 | |
| SCHEMBL1412882 | 0.79 | P2RX7 (0.68) | P2RX7ABCB11HIF1AKDM4EMEN1 | |
| SCHEMBL7085989 | 0.78 | P2RX7 (0.46) | P2RX7ABCB11KDM4EMEN1ALDH1A1 | |
| SCHEMBL1412952 | 0.77 | P2RX7 (0.79) | P2RX7ABCB11TP53 | |
| SCHEMBL1412897 | 0.76 | P2RX7 (0.84) | P2RX7ABCB11KDM4EMEN1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1448535-B1 | BENZAMIDE AND HETEROARYLAMIDE AS P2X7 RECEPTOR ANTAGONISTS | PFIZER PROD INC (US) | 2011-03-16 | — | — | EP | disclosed |
| US-20030186981-A1 | Benzamide, heteroarylamide and reverse amides | PFIZER INC. | 2003-10-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030186981-A1 | Benzamide, heteroarylamide and reverse amides | P2RX7, P2RX5, P2RX2 | P2RX7 1/4885ABCB11 866/4885HIF1A 59/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.